CA 15-3 prognostic biomarker in SARS-CoV-2 pneumonia [PDF]
Scientific Reports, 2022 The severity of lung involvement is the main prognostic factor in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Carbohydrate antigen 15-3 (CA 15-3), a marker of lung damage and fibrosis, could help predict the prognosis of SARS ...
José Antonio Ros-Lucas +16 more
doaj +5 more sources
Longitudinal evaluation of external quality assessment results for CA 15-3, CA 19-9, and CA 125 [PDF]
Frontiers in Molecular BiosciencesBackgroundTumor markers are established laboratory tools that help to diagnose, estimate prognosis, and monitor the course of cancer. For meaningful decision-making in patient care, it is essential that methods and analytical platforms demonstrate high ...
Marcel Kremser +8 more
doaj +5 more sources
Association of tumor markers CA 15-3, CEA, and CA 125 with [18F]NaF PET findings in breast cancer patients [PDF]
Frontiers in OncologyIntroductionBreast cancer often metastasizes to bone, and [18F]NaF PET is commonly used to detect skeletal involvement. This study examines the association of serum CA 15-3, CEA, and CA 125 with [18F]NaF PET findings in breast cancer to guide clinical ...
Arvin Naeimi +9 more
doaj +2 more sources
Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance [PDF]
Breast, 2020 Background: Serum tumour markers, cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) are not routinely recommended for detecting breast cancer recurrence and monitoring treatment. In this study, we aim to evaluate the diagnostic accuracy of
J.X. Hing +6 more
doaj +2 more sources
CA 15 − 3 may be a promising biomarker for differentiating distant organ metastasis in breast cancer at initial diagnosis [PDF]
BMC CancerBackground Imaging techniques for breast cancer identify distant organ metastasis, but can be time-consuming and costly. This study compares clinicopathological and laboratory data between metastatic and nonmetastatic breast cancer patients at initial ...
Serkan Yilmaz, Mesut Yur
doaj +2 more sources
CA 15–3: A Prognostic Marker in Breast Cancer
The International Journal of Biological Markers, 2000 CA 15–3 (also known as MUC1) is the most widely used serum marker in breast cancer. MUC1 is a large transmembrane glycoprotein which is frequently overexpressed and aberrantly glycosylated in cancer.
M.J. Duffy +4 more
doaj +3 more sources
Tumor marker CA 15-3 in breast cancer patients [PDF]
Acta Medica Academica, 2015 Objective. The aim of this study was to determine whether there is a correlation between the serum concentration of the tumor marker CA 15-3 and breast cancer, which has not been proven by the existence of regional and distant metastases, and breast ...
Hanifa Fejzić +3 more
doaj +4 more sources
Electrochemical immunosensor for detection of CA 15-3 biomarker in point-of-care
Sensing and Bio-Sensing Research, 2021 This work reports the development of a simple and rapid electrochemical immunosensor for the determination of breast cancer biomarker Cancer Antigen 15–3 (CA 15–3). Disposable and cost-effective chips, consisting of gold screen-printed electrodes (AuSPEs)
Tânia S.C.R. Rebelo +3 more
doaj +2 more sources
Avaliação dos valores sérico e pleural dos marcadores tumorais CEA, CYFRA21-1 e CA 15-3 em portadores de derrame pleural [PDF]
, 2007 OBJECTIVE: To determine the levels of the tumor markers carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1) and carbohydrate antigen 15-3 (CA 15-3) in the blood and pleural fluid of patients with benign or malignant pleural effusion ...
Isabella Coimbra Wagner +4 more
openalex +4 more sources
Comparison of the performance of three cancer antigen (CA) 15-3 immunoassays
Journal of Health Sciences, 2016 Introduction: In the present study we investigated the performance, precision, and recovery of three different automated methods in determining cancer antigen (CA) 15-3 levels. Methods: Serum samples were obtained from 60 hospitalized female patients. As
Nafija Serdarevic +2 more
doaj +3 more sources